Novel exendin agonist formulations and methods administration thereof

A technology of agonists and preparations, applied in pharmaceutical formulations, hormone peptides, drug combinations, etc., can solve problems such as the unique properties of hindered peptides and proteins

Inactive Publication Date: 2002-12-11
AMYLIN PHARMACEUTICALS LLC
View PDF3 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this is hindered by the unique properties of peptides and proteins, making them unable to be administered gastrointestinally like the currently widely used small molecule drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel exendin agonist formulations and methods administration thereof
  • Novel exendin agonist formulations and methods administration thereof
  • Novel exendin agonist formulations and methods administration thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-e

[0154] Preparation of Example 1-exendin-3 His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met GluGlu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyPro Ser Ser Ser Gly Ala Pro Pro Pro Ser-NH 2 [SEQ.ID.NO.1]

[0155]Using Fmoc-protected amino acid (Applied Biosystems, Inc.) in 4-(2'-4'-dimethoxyphenyl)-Fmocaminomethylphenoxyacetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) to synthesize the above amide peptide. In general, one coupling cycle was used throughout the synthesis, and Fast Moc (HBTU activated) chemistry was utilized. The extended peptide chain was deprotected (removal of the Fmoc group) using piperidine. Finally, triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid were applied according to standard methods (Introduction to Lysis Technology, Applied Biosystems, Inc.) (15 mL) of the mixture to deprotect the completed peptide resin. The peptide was precipitated with ether / w...

Embodiment 2

[0158] Example 2- Preparation of exendin-4 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met GluGlu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyPro Ser Ser Ser Gly Ala Pro Pro Pro Ser-NH 2 [SEQ.ID.NO.2]

[0159] Using Fmoc-protected amino acid (Applied Biosystems, Inc.) in 4-(2'-4'-dimethoxyphenyl)-Fmocaminomethylphenoxyacetamide norleucine MBHA resin (Novabiochem, 0.55 mmole / g) to assemble and synthesize the above amide peptide, according to the method similar to that of exendin-3 described in Example 1, the peptide was cleaved from the resin, deprotected and purified. Solvent A (0.1% TFA in water) and solvent B (0.1% TFA in ACN) were used in the analysis. Analytical RP-HPLC (gradient 36%-46% solvent B in solvent A in 30 minutes) of the lyophilized peptide gave the product peptide with an observed retention time of 14.9 minutes. Electron spray mass spectrometry (M): the calculated value is 4186.6; the measured value is 8186.0-4186.8 (four ba...

Embodiment 3

[0160] Embodiment 3-exendin-4 in Gila deformity lizard body

[0161] circulating diet-associated peptide

[0162] This experiment is to investigate whether exendin-4 has a metabolic effect in the Gila deformity lizard itself. To investigate whether exendin-4 is present in the blood of Gila teratophiles under the influence of feeding, blood was taken from a lizard fasted for 7 weeks, before and 30 minutes after feeding a small rat. Full-length exendin-4 in plasma was analyzed using immunoradiometric assays of monoclonal antibody pairs directed against exendin-4 N-terminal and C-terminal epitopes. The plasma concentration of exendin-4 in fasted lizards was 76pg / mL, close to the lower limit of quantitation. After eating, the plasma concentration increased 300-fold to 23,120 pg / mL.

[0163] In a second experiment, 2 lizards were fasted for 5 weeks and serial blood samples were taken before and after feeding 1 or 2 small rats (47-49 g). Immediately af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and / or slowing gastric empyting or inhibiting food intake.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Application 60 / 116,380, filed January 14, 1999, entitled "Novel Exendin Agonist Formulations and Methods of Administering Same" and filed January 14, 1999, entitled " Use of exendin and agonists thereof for the regulation of triglyceride levels and the treatment of lipid disorders" US Provisional Application 60 / [not yet assigned], the contents of which are incorporated herein by reference. field of invention [0003] The present invention relates to novel exendin and peptide exendin agonist formulations, dosages, and formulations that are biologically active and can be delivered by injectable and non-injective routes such as the respiratory, oral, and gastrointestinal tracts. These formulations and dosages and methods of administration are useful in the treatment of diabetes, including type I and type II diabetes mellitus, in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61KA61K9/14A61K9/19A61K38/00A61K38/17A61K38/22A61K38/26A61K47/02A61K47/10A61K47/12A61K47/18A61K47/26A61K47/34A61PA61P3/04A61P3/10A61P5/50C07K14/575
CPCA61K38/2278A61P3/04A61P5/50A61P3/10A61K38/17
Inventor A·杨J·J·利塔利恩O·科特曼
Owner AMYLIN PHARMACEUTICALS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap